•
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot firm Youjia (Hangzhou) Biomedical Technology Co., Ltd to jointly develop an antibody-oligonucleotide conjugate (AOC) for the treatment of metabolic diseases. This collaboration aims to leverage the combined expertise of both companies to advance innovative therapeutic…
•
China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) to develop LXP2311 and LXP0531, long-acting drugs targeting asthma and chronic obstructive pulmonary disease (COPD) for the mainland Chinese market. Partnership FocusThe collaboration leverages Lexenpharm’s technical capabilities in respiratory diseases and Sun-Novo’s clinical…
•
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) has secured approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials for ZM001, a CD19-targeted chimeric antigen receptor (CAR)-T therapy, in the treatment of systemic lupus erythematosus (SLE). The therapy, co-developed with Beijing-based gene therapy specialist Immunochina Pharmaceuticals, is…
•
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its investigational drug candidate STC008. This study will focus on the treatment of tumor cachexia…
•
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a pharmaceutical company based in China, has entered into another partnership with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940). The two companies had previously agreed to collaborate on the development of modified drugs and are now expanding their collaboration…
•
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co. Ltd (SHE: 002940) concerning Sun-Novo’s drug candidate, NHKC-1. This development marks a collaborative effort between the two companies to co-develop a treatment for primary hypertension. NHKC-1: A Drug…
•
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with Japanese firm Kaneka Corporation, securing exclusive patent rights and technical know-how for two skin patch drugs, SN001 and SN002. The agreement covers the Chinese mainland, Hong Kong, and Macao markets, expanding the reach of these…
•
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the Marketing Authorization Holder (MAH) rights to Beijing Baiao Pharmaceuticals Co., Ltd’s generic version of Takeda Pharmaceutical Co., Ltd’s azilsartan (20mg, 40mg) for RMB 36.05 million (USD 5.04 million). The deal is structured to transfer the…
•
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study assessing its Category 1 drug candidate STC007. The study will focus on moderate to severe chronic kidney disease-associated pruritus (CKD-aP) in adults receiving hemodialysis (HD).…